Resilience Secures Up to $825 Million to Accelerate Biomanufacturing Growth

National Resilience secures up to $825 million in debt financing to enhance biopharmaceutical manufacturing capabilities, marking a significant step in expanding access to complex medicines.

• National Resilience has announced a long-term debt financing agreement of up to $825 million with Oak Hill Advisors to bolster its financial position and growth strategy.
• This funding will specifically support Resiliences role as a Contract Development and Manufacturing Organization (CDMO), enhancing biomanufacturing efforts crucial for the biopharmaceutical sector.
• The financing is part of Resiliences broader initiative to improve access to complex medicines, a critical need identified in regions including Toronto and Cincinnati.